Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OPP | 6.88 | 0.06 | +0.88% |
| RiverNorth/DoubleLine Strategic Opportunity Fund | |||
| WABF | 23.76 | 0.01 | +0.06% |
| Western Asset Bond ETF (WABF) | |||
| BKUI | 49.56 | 0.02 | +0.04% |
| BNY Mellon Ultra Short Income ETF (BKUI) | |||
| GSLC | 140.23 | -1.57 | -1.11% |
| Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF (GSLC) | |||
| TBLU | 51.68 | -0.60 | -1.15% |
| Tortoise Global Water ETF (TBLU) | |||
A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with MGTX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then MGTX could also see price increases.
| Ticker / NAME | Correlation To PTGX | 1D Price Change % | ||
|---|---|---|---|---|
| PTGX | 100% | -0.13% | ||
| MGTX - PTGX | 50% Loosely correlated | -3.20% | ||
| DYN - PTGX | 49% Loosely correlated | -4.07% | ||
| ARQT - PTGX | 48% Loosely correlated | +0.66% | ||
| DNTH - PTGX | 47% Loosely correlated | -2.87% | ||
| KYTX - PTGX | 46% Loosely correlated | -1.26% | ||
More | ||||
a developer of disulfide-rich peptides
Industry Biotechnology
Be on the lookout for a price bounce soon.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTGX advanced for three days, in 231 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
PTGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PTGX as a result. In 65 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for PTGX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
PTGX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PTGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.153) is normal, around the industry mean (3.592). PTGX has a moderately high P/E Ratio (108.230) as compared to the industry average of (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (34.130) is also within normal values, averaging (442.120).